Compare Abbott Laboratories (ABT) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Nuscale Power Corporation — how do they compare? Abbott Laboratories trades at $95.33 (market cap $166.94B), while Nuscale Power Corporation trades at $8.8 (market cap $3.10B). The key difference: Abbott Laboratories is far larger — about 53.9× Nuscale Power Corporation's market cap, and Abbott Laboratories pays a 2.63% dividend while Nuscale Power Corporation pays none. Which is the better fit depends on your goals.
| ABT | SMR | |
|---|---|---|
Market Cap | $166.94B | $3.10B |
Sector | Health | Utilities |
52-Week High | $136.62 | $53.43 |
52-Week Low | $82.57 | $8.96 |
Enterprise Value | $193.69B | $2.21B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
NuScale Power (SMR) trades at $9.61, down 1.54% on the day, reflecting ongoing bearish technical momentum. The company shows severe financial strain with a net income margin of -2,066.55% and negative cash flow from operations of $459.61 million in 2025. Despite this, analyst consensus remains optimistic with a $13.00 price target, and recent news highlights potential long-term growth from SMR technology commercialization and partnerships like ENTRA1.
The outlook is highly speculative; significant upside exists if NuScale successfully commercializes its reactors by the 2030s, but near-term risks include persistent losses, high cash burn, and execution hurdles. Investors face substantial volatility with the stock near its 52-week low, requiring high risk tolerance for potential multi-bagger returns amid operational and competitive challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
